Key insights
- Weight Watchers' Med+ program is now available via Eli Lilly's LillyDirect platform, integrating GLP-1 medication access with support services. This partnership aims to expand patient access to weight management solutions. While the integration addresses growing demand for GLP-1 drugs, Weight Watchers' stock has seen significant declines, suggesting the news has a neutral immediate impact on broader US equity markets, though it's a key development for the healthcare and pharmaceutical sectors.
NEW YORK - WW International, Inc. (NASDAQ:WW) announced Thursday that its Weight Watchers Med+ program is now accessible through Eli Lilly and Company’s digital healthcare platform, LillyDirect.
The integration allows LillyDirect users to connect with Weight Watchers Med+ program, which combines GLP-1 medication access with clinical and behavioral support services, according to a press release statement.
Through LillyDirect, patients can access independent care options, pharmacy fulfillment resources and educational materials. Weight Watchers Med+ provides clinical care from licensed providers alongside nutrition and community support for patients seeking prescription weight management medications.
"A seamless connection from LillyDirect is central to expanding access while ensuring patients are supported beyond the prescription," said Scott Honken, PharmD, Chief Commercial Officer at Weight Watchers.
The Weight Watchers Med+ platform includes GLP-1 Success program support and serves members who are exploring medication, currently taking GLP-1 or other obesity medications, or seeking long-term support.
Weight Watchers operates as a weight management program offering clinical interventions and access to GLP-1 medications when clinically appropriate. The company has operated since 1963 and provides services directly to consumers and through Weight Watchers for Business platform for employers, health plans and payers. With a market capitalization of $161 million and revenue of $692 million over the last twelve months, the company maintains impressive gross profit margins of 72%, though it currently operates with significant debt.
The integration comes as demand for GLP-1 medications continues to grow in the weight management sector. Despite this strategic partnership, WW shares have declined 38% over the past six months and are down 45% year-to-date. According to InvestingPro analysis, the stock appears undervalued at current levels, with a Fair Value suggesting potential upside. Investors can access the comprehensive Pro Research Report on WW, one of 1,400+ US equities covered with detailed analysis and actionable intelligence.
In other recent news, WW International reported its first-quarter earnings for 2026, highlighting a strategic shift despite a decline in revenue. The company announced a revenue of $168 million, marking a 10% decrease from the previous year. This decline comes as WW International focuses on transitioning to higher-value membership tiers. Additionally, the company has entered into a settlement agreement with its former CEO, Tara Comonte, who resigned effective March 31, 2026. The settlement includes a mutual release of claims and stipulates that Ms. Comonte will receive a total of $1,850,000 in cash, distributed in two installments, along with $150,000 for her legal fees. These developments were disclosed in a filing with the Securities and Exchange Commission. The company’s recent strategic decisions and financial results have been closely watched by investors and analysts.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
The fastest way to find out is with our Fair Value calculator. We use a mix of 17 proven industry valuation models for maximum accuracy. Get the bottom line for WW plus thousands of other stocks and find your next hidden gem with massive upside.